Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

Background. Palivizumab is a US Food and Drug Administration–approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with enhanced antiviral activity, has recently been tested in humans...

詳細記述

保存先:
書誌詳細
主要な著者: Zhu, Qing, McAuliffe, Josie M., Patel, Nita K., Palmer-Hill, Frances J., Yang, Chin-fen, Liang, Brandon, Su, Lan, Zhu, Wei, Wachter, Leslie, Wilson, Susan, MacGill, Randall S., Krishnan, Subramaniam, McCarthy, Michael P., Losonsky, Genevieve A., Suzich, JoAnn A.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2011
主題:
Major Articles and Brief Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3072724/
https://ncbi.nlm.nih.gov/pubmed/21208913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiq100
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料